Your browser doesn't support javascript.
loading
A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes.
Ferreira, Ricardo C; Guo, Hui; Coulson, Richard M R; Smyth, Deborah J; Pekalski, Marcin L; Burren, Oliver S; Cutler, Antony J; Doecke, James D; Flint, Shaun; McKinney, Eoin F; Lyons, Paul A; Smith, Kenneth G C; Achenbach, Peter; Beyerlein, Andreas; Dunger, David B; Clayton, David G; Wicker, Linda S; Todd, John A; Bonifacio, Ezio; Wallace, Chris; Ziegler, Anette-G.
Afiliación
  • Ferreira RC; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Guo H; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Coulson RM; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.Cambridge Institute for Medical Research and Department of Medicine, University of Ca
  • Smyth DJ; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Pekalski ML; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Burren OS; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Cutler AJ; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Doecke JD; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.The Australian E-Health Research Centre, Royal Brisbane and Women's Hospital, Queensl
  • Flint S; Cambridge Institute for Medical Research and Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, U.K.
  • McKinney EF; Cambridge Institute for Medical Research and Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, U.K.
  • Lyons PA; Cambridge Institute for Medical Research and Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, U.K.
  • Smith KG; Cambridge Institute for Medical Research and Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, U.K.
  • Achenbach P; Institute of Diabetes Research, Helmholtz Zentrum München, Neuherberg, and Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, München, Germany.
  • Beyerlein A; Institute of Diabetes Research, Helmholtz Zentrum München, Neuherberg, and Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, München, Germany.
  • Dunger DB; Department of Paediatrics, School of Clinical Medicine, University of Cambridge, Cambridge, U.K.
  • Clayton DG; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Wicker LS; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Todd JA; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K. john.todd@cimr.cam.ac.uk chris.wallace@cimr.cam.ac.uk anette-g.ziegler@helmholtz-mue
  • Bonifacio E; CRTD-DFG Research Center for Regenerative Therapies Dresden and Paul Langerhans Institute Dresden, Technische Universität Dresden, Dresden, Germany.
  • Wallace C; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K. john.todd@cimr.cam.ac.uk chris.wallace@cimr.cam.ac.uk anette-g.ziegler@helmholtz-mue
  • Ziegler AG; Institute of Diabetes Research, Helmholtz Zentrum München, Neuherberg, and Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, München, Germany john.todd@cimr.cam.ac.uk chris.wallace@cimr.cam.ac.uk anette-g.ziegler@helmholtz-muenchen.de.
Diabetes ; 63(7): 2538-50, 2014 Jul.
Article en En | MEDLINE | ID: mdl-24561305
ABSTRACT
Diagnosis of the autoimmune disease type 1 diabetes (T1D) is preceded by the appearance of circulating autoantibodies to pancreatic islets. However, almost nothing is known about events leading to this islet autoimmunity. Previous epidemiological and genetic data have associated viral infections and antiviral type I interferon (IFN) immune response genes with T1D. Here, we first used DNA microarray analysis to identify IFN-ß-inducible genes in vitro and then used this set of genes to define an IFN-inducible transcriptional signature in peripheral blood mononuclear cells from a group of active systemic lupus erythematosus patients (n = 25). Using this predefined set of 225 IFN signature genes, we investigated the expression of the signature in cohorts of healthy controls (n = 87), patients with T1D (n = 64), and a large longitudinal birth cohort of children genetically predisposed to T1D (n = 109; 454 microarrayed samples). Expression of the IFN signature was increased in genetically predisposed children before the development of autoantibodies (P = 0.0012) but not in patients with established T1D. Upregulation of IFN-inducible genes was transient, temporally associated with a recent history of upper respiratory tract infections (P = 0.0064), and marked by increased expression of SIGLEC-1 (CD169), a lectin-like receptor expressed on CD14(+) monocytes. DNA variation in IFN-inducible genes altered T1D risk (P = 0.007), as exemplified by IFIH1, one of the genes in our IFN signature for which increased expression is a known risk factor for disease. These findings identify transient increased expression of type I IFN genes in preclinical diabetes as a risk factor for autoimmunity in children with a genetic predisposition to T1D.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interferón Tipo I / Autoinmunidad / Diabetes Mellitus Tipo 1 / Transcriptoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Año: 2014 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interferón Tipo I / Autoinmunidad / Diabetes Mellitus Tipo 1 / Transcriptoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Año: 2014 Tipo del documento: Article País de afiliación: Reino Unido